GlassScriptPhysician profile
Abdul Nawabi
NPI 1184699506
$5,675.92
in general payments reported to CMS, 2019-2025
34 companies · $15.51 in 2025
The $15.51 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,514 · 2020: $990 · 2021: $1,727 · 2022: $710 · 2023: $573 · 2024: $147 · 2025: $15.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $735.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $2,330.83 | 2019-2023 | Xeomin |
| Allergan, INC. | $466.09 | 2019-2022 | |
| Amgen INC. | $433.74 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $378.75 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $327.90 | 2019-2021 | |
| Abbvie INC. | $311.56 | 2021-2025 | |
| Currax Pharmaceuticals LLC | $144.69 | 2019-2022 | |
| Pfizer INC. | $113.12 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $112.75 | 2020-2021 | |
| Amarin Pharma, INC. | $98.33 | 2019-2021 | |
| Novo Nordisk INC | $96.55 | 2019-2021 | |
| Galderma Laboratories, L.P. | $84.11 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $81.32 | 2019-2020 | |
| Kvk-Tech, INC. | $78.57 | 2019 | |
| Eisai INC. | $66.52 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $57.54 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.76 | 2020-2021 | |
| Gilead Sciences, INC. | $50.34 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $47.29 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $39.15 | 2019-2020 | |
| Vertiflex, INC. | $35.70 | 2019 | |
| Genentech USA, INC. | $34.28 | 2020-2021 | |
| Mannkind Corporation | $31.98 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.60 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $23.18 | 2020 | |
| Daiichi Sankyo INC. | $23.10 | 2021 | |
| Ironwood Pharmaceuticals, INC | $22.29 | 2020 | |
| Lucid Diagnostics INC. | $19.16 | 2023 | |
| Therapeuticsmd, INC. | $17.79 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $16.09 | 2019 | |
| Genzyme Corporation | $15.28 | 2022 | |
| Heartflow, INC. | $13.21 | 2022 | |
| Bausch Health US, LLC | $12.22 | 2019 | |
| Sanofi Pasteur INC. | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Nawabi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.